Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12456434 | 0.84 | CYP1A2 (0.71) | CYP1A2GAACYP3A4JAK3PDE4A | |
| SCHEMBL12456432 | 0.84 | CYP1A2 (0.51) | CYP1A2CYP11B2GAAALDH1A1JAK3 | |
| SCHEMBL14916729 | 0.84 | CYP1A2 (0.75) | CYP1A2GAACTSLCTSSCTSK | |
| SCHEMBL1715467 | 0.84 | CYP1A2 (0.80) | CYP1A2GAACTSLCTSBCTSS | |
| SCHEMBL12456469 | 0.81 | CYP1A2 (0.65) | CYP1A2GAAJAK3IDO1PDE4A | |
| SCHEMBL12456042 | 0.80 | CYP19A1 (0.52) | CYP1A2GAAALDH1A1JAK3 | |
| SCHEMBL193553 | 0.80 | CYP1A2 (0.54) | CYP1A2GAAALDH1A1JAK3PDE4A | |
| SCHEMBL12456426 | 0.78 | CYP1A2 (0.61) | CYP1A2CYP11B2GAACYP11B1PDE4A | |
| SCHEMBL12456468 | 0.78 | CYP1A2 (0.61) | CYP1A2CYP11B2GAACYP2A6CYP11B1 | |
| SCHEMBL12456473 | 0.77 | CYP1A2 (0.56) | CYP1A2CYP11B2GAAJAK3CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357917-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3357917-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10023556-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023556-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3124481-B1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-3124481-B1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-3124481-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-3124481-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2824102-B1 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS INC (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2824102-B1 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS INC (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20160376252-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-9481664-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9108944-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108944-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150182529-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2015-07-02 | — | — | US | disclosed |
| EP-2824102-A1 | Androgen receptor modulators and uses thereof | Aragon Pharmaceuticals, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2824102-A1 | Androgen receptor modulators and uses thereof | Aragon Pharmaceuticals, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20130116258-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116258-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116258-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | AR, ESRRA, NR5A1 | CYP1A2 767/4885CYP11B2 51/4885GAA 3086/4885 |
| US-20150182529-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | AR, ESRRA, NR5A1 | CYP1A2 767/4885CYP11B2 51/4885GAA 3086/4885 |
| US-10023556-B2 | Androgen receptor modulators and uses thereof | AR, ESRRA, NR5A1 | CYP1A2 767/4885CYP11B2 51/4885GAA 3086/4885 |
| US-20160376252-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | AR, ESRRA, NR5A1 | CYP1A2 767/4885CYP11B2 51/4885GAA 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.